FLUPHENAZINE DECANOATE

Post-LOE

fluphenazine decanoate

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

Aug 2001

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

FLUPHENAZINE DECANOATE (fluphenazine decanoate) by Viatris (2) is clinical pharmacology the basic effects of fluphenazine decanoate appear to be no different from those of fluphenazine hydrochloride, with the exception of duration of action. First approved in 2001.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY The basic effects of fluphenazine decanoate appear to be no different from those of fluphenazine hydrochloride, with the exception of duration of action. The esterification of fluphenazine markedly prolongs the drug's duration of effect without unduly attenuating its…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on FLUPHENAZINE DECANOATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.